HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
05 07 2019
Historique:
received: 30 05 2019
revised: 02 07 2019
accepted: 03 07 2019
entrez: 10 7 2019
pubmed: 10 7 2019
medline: 10 7 2019
Statut: epublish

Résumé

Abscission is the final step of cell division, mediating the physical separation of the two daughter cells. A key player in this process is the microtubule-severing enzyme spastin that localizes at the midbody where its activity is crucial to cut microtubules and culminate the cytokinesis. Recently, we demonstrated that HIPK2, a multifunctional kinase involved in several cellular pathways, contributes to abscission and prevents tetraploidization. Here, we show that HIPK2 binds and phosphorylates spastin at serine 268. During cytokinesis, the midbody-localized spastin is phosphorylated at S268 in HIPK2-proficient cells. In contrast, no spastin is detectable at the midbody in HIPK2-depleted cells. The non-phosphorylatable spastin-S268A mutant does not localize at the midbody and cannot rescue HIPK2-depleted cells from abscission defects. In contrast, the phosphomimetic spastin-S268D mutant localizes at the midbody and restores successful abscission in the HIPK2-depleted cells. These results show that spastin is a novel target of HIPK2 and that HIPK2-mediated phosphorylation of spastin contributes to its midbody localization for successful abscission.

Identifiants

pubmed: 31284535
pii: cells8070684
doi: 10.3390/cells8070684
pmc: PMC6678495
pii:
doi:

Substances chimiques

Carrier Proteins 0
Serine 452VLY9402
HIPK2 protein, human EC 2.7.1.-
Protein Serine-Threonine Kinases EC 2.7.11.1
Spastin EC 3.6.4.3
SPAST protein, human EC 5.6.1.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Hum Mol Genet. 2004 Sep 15;13(18):2121-32
pubmed: 15269182
Exp Cell Res. 2005 Oct 1;309(2):358-69
pubmed: 16026783
Cell Death Differ. 2006 Nov;13(11):1994-7
pubmed: 16729035
BMC Biol. 2008 Jul 09;6:31
pubmed: 18613979
Nat Struct Mol Biol. 2008 Dec;15(12):1278-86
pubmed: 18997780
Traffic. 2009 Jan;10(1):42-56
pubmed: 19000169
J Neurochem. 2009 Mar;108(5):1277-88
pubmed: 19141076
Nat Cell Biol. 2009 Apr;11(4):409-19
pubmed: 19287380
Hum Mol Genet. 2010 Jul 15;19(14):2767-79
pubmed: 20430936
Science. 2011 Mar 25;331(6024):1616-20
pubmed: 21310966
J Neurochem. 2011 May;117(4):724-34
pubmed: 21395583
Mol Biol Cell. 2012 Mar;23(6):1024-34
pubmed: 22278743
PLoS One. 2012;7(5):e36505
pubmed: 22574173
Mol Cell. 2012 Jul 13;47(1):87-98
pubmed: 22658722
J Exp Clin Cancer Res. 2012 Aug 13;31:63
pubmed: 22889244
J Mol Cell Biol. 2013 Feb;5(1):27-38
pubmed: 23000554
J Mol Biol. 2013 Jan 23;425(2):214-21
pubmed: 23178168
Biochim Biophys Acta. 2013 Jun;1833(6):1443-53
pubmed: 23485397
J Cell Biol. 2013 Aug 5;202(3):527-43
pubmed: 23897888
Dev Cell. 2014 Dec 8;31(5):525-38
pubmed: 25490264
Oncotarget. 2015 Apr 30;6(12):10320-34
pubmed: 25868975
PLoS Genet. 2015 Apr 13;11(4):e1005149
pubmed: 25875445
Semin Cell Dev Biol. 2016 May;53:57-63
pubmed: 26802517
Chromosoma. 2017 Feb;126(1):93-103
pubmed: 27106516
Trends Cell Biol. 2017 Jan;27(1):1-11
pubmed: 27810282
Cold Spring Harb Perspect Biol. 2017 Oct 3;9(10):null
pubmed: 28007751
Curr Top Dev Biol. 2017;123:73-103
pubmed: 28236976
Oncogene. 2017 Aug 24;36(34):4819-4827
pubmed: 28436952
Semin Cell Dev Biol. 2018 Feb;74:50-65
pubmed: 28843980
Protein Sci. 2018 Mar;27(3):725-737
pubmed: 29277937
Oncogene. 2018 Jun;37(26):3562-3574
pubmed: 29563611
Cell Rep. 2018 Aug 14;24(7):1756-1764
pubmed: 30110633
J Cell Biol. 2018 Dec 3;217(12):4057-4069
pubmed: 30373906
Dev Cell. 2018 Dec 3;47(5):547-563.e6
pubmed: 30513301

Auteurs

Alessandra Pisciottani (A)

Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), c/o Sapienza University, 00185 Rome, Italy.

Loredana Biancolillo (L)

Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), c/o Sapienza University, 00185 Rome, Italy.

Manuela Ferrara (M)

Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), c/o Sapienza University, 00185 Rome, Italy.

Davide Valente (D)

Unit of Cellular Networks and Molecular Therapeutic Targets; IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.

Francesca Sardina (F)

Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), c/o Sapienza University, 00185 Rome, Italy.

Laura Monteonofrio (L)

Unit of Cellular Networks and Molecular Therapeutic Targets; IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.

Serena Camerini (S)

Core Facilities, Italian National Institute of Health, 00161 Rome, Italy.

Marco Crescenzi (M)

Core Facilities, Italian National Institute of Health, 00161 Rome, Italy.

Silvia Soddu (S)

Unit of Cellular Networks and Molecular Therapeutic Targets; IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.

Cinzia Rinaldo (C)

Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), c/o Sapienza University, 00185 Rome, Italy. cinzia.rinaldo@uniroma1.it.
Unit of Cellular Networks and Molecular Therapeutic Targets; IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy. cinzia.rinaldo@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH